(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 247.24% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.51%.
Precigen's revenue in 2025 is $6,309,000.On average, 6 Wall Street analysts forecast PGEN's revenue for 2025 to be $4,848,103,285, with the lowest PGEN revenue forecast at $693,496,018, and the highest PGEN revenue forecast at $6,513,909,027. On average, 6 Wall Street analysts forecast PGEN's revenue for 2026 to be $39,270,981,144, with the lowest PGEN revenue forecast at $22,191,872,577, and the highest PGEN revenue forecast at $58,887,011,369.
In 2027, PGEN is forecast to generate $99,396,378,259 in revenue, with the lowest revenue forecast at $86,520,704,740 and the highest revenue forecast at $111,939,456,749.